1. Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18:269-82.

https://doi.org/10.1038/nrc.2018.11

PMid:29497144 

2. Fonseca FP, Sena Filho M, Altemani A, Speight PM, Vargas PA. Molecular signature of salivary gland tumors: potential use as diagnostic and prognostic marker. J Oral Pathol Med. 2016;45:101-10.

https://doi.org/10.1111/jop.12329

PMid:25990369 

3. Ijsselsteijn R, Jansen JG, de Wind N. DNA mismatch repair-dependent DNA damage responses and cancer. DNA Repair (Amst). 2020;93:102923.

https://doi.org/10.1016/j.dnarep.2020.102923

PMid:33087264 

4. Wagner VP, Webber LP, Salvadori G, Meurer L, Fonseca FP, Castilho RM, et al. Overexpression of MutSα Complex Proteins Predicts Poor Prognosis in Oral Squamous Cell Carcinoma. Medicine (Baltimore). 2016;95:e3725.

https://doi.org/10.1097/MD.0000000000003725

PMid:27258499 PMCid:PMC4900707

5. Amaral-Silva GKD, Sánchez-Romero C, Wagner VP, Martins MD, Pontes HAR, Fregnani ER, et al. Prognostic significance of hMSH2, hMSH3, and hMSH6 expression in ameloblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124:286-95.

https://doi.org/10.1016/j.oooo.2017.05.511

PMid:28734697 

6. Cilona M, Locatello LG, Novelli L, Gallo O. The Mismatch Repair System (MMR) in Head and Neck Carcinogenesis and Its Role in Modulating the Response to Immunotherapy: A Critical Review. Cancers (Basel). 2020;12:3006.

https://doi.org/10.3390/cancers12103006

PMid:33081243 PMCid:PMC7602801

7. Ohki K, Kumamoto H, Ichinohasama R, Suzuki M, Yamaguchi T, Echigo S, et al. Genetic analysis of DNA microsatellite loci in salivary gland tumours: comparison with immunohistochemical detection of hMSH2 and p53 proteins. Int J Oral Maxillofac Surg. 2001;30:538-44.

https://doi.org/10.1054/ijom.2001.0161

PMid:11829237 

8. Castrilli G, Fabiano A, La Torre G, Marigo L, Piantelli C, Perfetti G, et al. Expression of hMSH2 and hMLH1 proteins of the human DNA mismatch repair system in salivary gland tumors. J Oral Pathol Med. 2002;31:234-8.

https://doi.org/10.1034/j.1600-0714.2002.310407.x

PMid:12076327 

9. Tobón-Arroyave SI, Flórez-Moreno GA, Jaramillo-Cárdenas JF, Arango-Uribe JD, Isaza-Guzmán DM, Rendón-Henao J; POPCAD Research Group. Expression of hMLH1 and hMSH2 proteins in pleomorphic adenoma of minor salivary glands: relationship with clinical and histologic findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108:227-36.

https://doi.org/10.1016/j.tripleo.2009.02.033

PMid:19464205 

10. Huang SH, O'Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18:40.

https://doi.org/10.1007/s11864-017-0484-y

PMid:28555375 

11. Kawakita D, Murase T, Ueda K, Kano S, Tada Y, Tsukahara K, et al. The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan. Int J Clin Oncol. 2020;25:1774-85.

https://doi.org/10.1007/s10147-020-01731-9

PMid:32613404 

12. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 1998;82:1217-24.

https://doi.org/10.1002/(SICI)1097-0142(19980401)82:7<1217::AID-CNCR2>3.0.CO;2-C

PMid:9529011

13. Paiva-Fonseca F, de Almeida OP, Ayroza-Rangel AL, Agustin-Vargas P. Tissue microarray construction for salivary gland tumors study. Med Oral Patol Oral Cir Bucal. 2013;18:e1-6.

https://doi.org/10.4317/medoral.18204

PMid:22926480 PMCid:PMC3548626

14. Fonseca FP, de Andrade BA, Rangel AL, Della Coletta R, Lopes MA, de Almeida OP, et al. Tissue microarray is a reliable method for immunohistochemical analysis of pleomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:81-8.

https://doi.org/10.1016/j.oooo.2013.08.029

PMid:24332331 

15. Rito M, Fonseca I. Salivary Gland Neoplasms: Does Morphological Diversity Reflect Tumor Heterogeneity. Pathobiology. 2018;85:85-95.

https://doi.org/10.1159/000479070

PMid:28930752 

16. Uehara H, Miyamoto M, Kato K, Cho Y, Kurokawa T, Murakami S, et al. Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma. J Surg Oncol. 2005;92:109-15.

https://doi.org/10.1002/jso.20332

PMid:16231369 

17. Kawakami T, Shiina H, Igawa M, Deguchi M, Nakajima K, Ogishima T, et al. Inactivation of the hMSH3 mismatch repair gene in bladder cancer. Biochem Biophys Res Commun. 2004;325:934-42.

https://doi.org/10.1016/j.bbrc.2004.10.114

PMid:15541380 

18. Ni H, Jiang B, Zhou Z, Yuan X, Cao X, Huang G, et al. Inactivation of MSH3 by promoter methylation correlates with primary tumor stage in nasopharyngeal carcinoma. Int J Mol Med. 2017;40:673-78.

https://doi.org/10.3892/ijmm.2017.3044

PMid:28656302 PMCid:PMC5547962

19. de Wind N, Dekker M, Claij N, Jansen L, van Klink Y, Radman M, Riggins G, et al. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet. 1999;23:359-62.

https://doi.org/10.1038/15544

PMid:10545954 

20. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123:2965-8.

https://doi.org/10.1172/JCI67201

PMid:23778141 PMCid:PMC3999050

21. Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791-8.

https://doi.org/10.1038/ng.2643

PMid:23685749 PMCid:PMC3708595

22. Vogelsang M, Paccez JD, Schäfer G, Dzobo K, Zerbini LF, Parker MI. Aberrant methylation of the MSH3 promoter and distal enhancer in esophageal cancer patients exposed to first-hand tobacco smoke. J Cancer Res Clin Oncol. 2014;140:1825-33.

https://doi.org/10.1007/s00432-014-1736-x

PMid:24934723